Latest news and articles about التكنولوجيا الحيوية from NEX English
MAK Capital, led by Michael Kaufman, urges Evotec SE to list its US unit on the stock market and accelerate its cost-cutting program after its shares plummeted by about 85% over the past five years.
Chinese biotech companies recorded a staggering $60 billion in cross-border licensing deals in the first quarter of 2026, reflecting a growing interest from multinational corporations in promising drug candidates from China. This marks a significant increase of 73% compared to the same period last year.
An Australian company has announced the development of a groundbreaking device that allows code execution on live human brain cells. This innovative system merges lab-grown neurons with silicon technology, opening new horizons in various fields.
Eli Lilly has announced a new partnership with Insilico Medicine aimed at developing drugs entirely designed by artificial intelligence. The deal, valued at approximately <strong>$2.75 billion</strong>, will enhance the company's efforts in discovering new treatments for various diseases.
Hua Medicine, a leading Chinese biotechnology firm, announced a remarkable revenue growth of <strong>93%</strong> for 2026. In an exclusive interview with Bloomberg's 'China' program, Strategic Director George Lin discussed the prospects of the company's main drug, Duzaglitin, and plans for expansion into new markets.
The Catholic Church has issued new guidelines permitting the use of animal organs in human transplants, emphasizing the need for medical and ethical standards. This announcement comes amid a growing demand for organ transplants worldwide.